This is a huge, missed opportunity for many of these patients if one considers that up to 90.0 % of NSCLC patients harbor Epidermal Growth Factor Receptor (EGFR) druggable mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.